ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...

For people facing aggressive bladder cancer that no longer responds to standard treatment, options have often been grim—either undergo life-changing surgery to remove the bladder or try less effective ...

Quality of life, sexual outcomes and self-image should be considered before choosing a treatment option for muscle-invasive bladder cancer, an expert said. For patients with muscle-invasive bladder ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease. For ...

Doctors consider surgery for interstitial cystitis (IC) as a last resort when other treatments, such as diet changes, medications, bladder instillations, and physical therapy, have failed to bring ...